Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.04 (-10.90%)
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
Rein Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Rein Therapeutics's total assets was $65.97M at Jun 30, 2026. For fiscal 2025 it was $24.16M, down 61.2% from the year before. The highest annual figure on record is $106.01M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.16M | -61.2% |
| FY2024 | Dec 31, 2024 | $62.19M | -41.3% |
| FY2023 | Dec 31, 2023 | $106.01M | +381.7% |
| FY2022 | Dec 31, 2022 | $22.01M | -54.6% |
| FY2021 | Dec 31, 2021 | $48.48M | +196.7% |
| FY2020 | Dec 31, 2020 | $16.34M | -38.3% |
| FY2019 | Dec 31, 2019 | $26.47M | -12.7% |
| FY2018 | Dec 31, 2018 | $30.31M | -42.5% |
| FY2017 | Dec 31, 2017 | $52.69M | +139.3% |
| FY2016 | Dec 31, 2016 | $22.02M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $65.97M | +14.8% |
| Q1 FY2026 | Mar 31, 2026 | $26.29M | -54.4% |
| Q4 FY2025 | Dec 31, 2025 | $24.16M | -61.2% |
| Q3 FY2025 | Sep 30, 2025 | $53.71M | -48.5% |
| Q2 FY2025 | Jun 30, 2025 | $57.48M | -47.5% |
| Q1 FY2025 | Mar 31, 2025 | $57.63M | -41.9% |
| Q4 FY2024 | Dec 31, 2024 | $62.19M | -41.3% |
| Q3 FY2024 | Sep 30, 2024 | $104.22M | +712.8% |
| Q2 FY2024 | Jun 30, 2024 | $109.40M | +681.9% |
| Q1 FY2024 | Mar 31, 2024 | $99.19M | +478.1% |
| Q4 FY2023 | Dec 31, 2023 | $106.01M | +381.7% |
| Q3 FY2023 | Sep 30, 2023 | $12.82M | -52.9% |
| Q2 FY2023 | Jun 30, 2023 | $13.99M | -58.6% |
| Q1 FY2023 | Mar 31, 2023 | $17.16M | -57.4% |
| Q4 FY2022 | Dec 31, 2022 | $22.01M | -54.6% |
| Q3 FY2022 | Sep 30, 2022 | $27.23M | -50.3% |
| Q2 FY2022 | Jun 30, 2022 | $33.77M | -44.2% |
| Q1 FY2022 | Mar 31, 2022 | $40.26M | -37.8% |
| Q4 FY2021 | Dec 31, 2021 | $48.48M | +196.7% |
| Q3 FY2021 | Sep 30, 2021 | $54.77M | +146.3% |
| Q2 FY2021 | Jun 30, 2021 | $60.53M | +131.7% |
| Q1 FY2021 | Mar 31, 2021 | $64.67M | +217.4% |
| Q4 FY2020 | Dec 31, 2020 | $16.34M | -38.3% |
| Q3 FY2020 | Sep 30, 2020 | $22.24M | -34.5% |
| Q2 FY2020 | Jun 30, 2020 | $26.13M | -35.0% |
| Q1 FY2020 | Mar 31, 2020 | $20.37M | -9.0% |
| Q4 FY2019 | Dec 31, 2019 | $26.47M | -12.7% |
| Q3 FY2019 | Sep 30, 2019 | $33.95M | -11.0% |
| Q2 FY2019 | Jun 30, 2019 | $40.19M | -5.6% |
| Q1 FY2019 | Mar 31, 2019 | $22.40M | -51.1% |
| Q4 FY2018 | Dec 31, 2018 | $30.31M | -42.5% |
| Q3 FY2018 | Sep 30, 2018 | $38.13M | -35.4% |
| Q2 FY2018 | Jun 30, 2018 | $42.58M | +181.9% |
| Q1 FY2018 | Mar 31, 2018 | $45.83M | +108.1% |
| Q4 FY2017 | Dec 31, 2017 | $52.69M | – |
| Q3 FY2017 | Sep 30, 2017 | $59.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.02M | – |
See a number that looks wrong?